Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608450 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
A Phase 3 study, sponsored by Cassiopea SpA.
- Completed
- Registry status
- Phase 3
- Development phase
- 708
- Enrollment target
NCT02608450: Completed Phase 3 study, sponsored by Cassiopea SpA.
NCT02608450 is a Phase 3 study that has completed, run by Cassiopea SpA. The registered enrollment target is 708 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608450, a Phase 3 study, has completed, sponsored by Cassiopea SpA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 708 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Primary Outcome
Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.
Interventions
- DRUG Vehicle cream
- DRUG CB-03-01 cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 708 participants |
| Start Date | 2016-01-21 |
| Est. Completion | 2018-04-11 |
| Phase | Phase 3 |
What the finished NCT02608450 record still lists
NCT02608450 is an interventional study that assigns participants to a tested intervention. The registered 708 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT02608450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02608450 about?
NCT02608450 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)". The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
What is the current status of trial NCT02608450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 708 participants. The study started on 2016-01-21. Estimated completion is 2018-04-11.
What interventions are being tested in trial NCT02608450?
The interventions under investigation include: Vehicle cream (DRUG), CB-03-01 cream, 1% (DRUG).
Who is sponsoring clinical trial NCT02608450?
This trial is sponsored by Cassiopea SpA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02608450's enrollment target sits among peer trials
708 505th of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI